Clinical Trials

1,314 enrolled

Prostatic Neoplasms

NCT06158841 2026-05-27

CERVINO

380 enrolled

Multiple Myeloma

NCT07095452 2026-05-27

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

660 enrolled

Multiple Myeloma

NCT07555938 2026-05-27

CEVOLUTION

380 enrolled

Phase 1 Not yet recruiting

Multiple Myeloma

NCT07609706 2026-05-27

A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

20 enrolled

Multiple Myeloma

NCT05319730 2026-05-26

MK-3475-06B

230 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06353386 2026-05-26

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06788912 2026-05-26

MK-3475-01E

Phase 2 Recruiting

60 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07227311 2026-05-26

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Phase 2 Recruiting

200 enrolled

Multiple Myeloma

NCT07570173 2026-05-26

MK-1045-005

Phase 2/3 Recruiting

340 enrolled

Burkitt Lymphoma

NCT01946477 2026-05-22

POM MM 014

Phase 2 Completed

186 enrolled 17 charts

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT06152575 2026-05-22

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06305754 2026-05-22

MK-2870-009

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07138209 2026-05-22

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

228 enrolled

Multiple Myeloma, Recurrence

NCT06433947 2026-05-19

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Recruiting

130 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07387926 2026-05-19

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

50 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05623020 2026-05-14

MagnetisMM-6

1,116 enrolled

Multiple Myeloma

NCT06615479 2026-05-13

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

261 enrolled

Multiple Myeloma, Recurrence

NCT03934684 2026-05-11

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Phase 4 Completed

101 enrolled 14 charts

Multiple Myeloma

NCT04181827 2026-05-11

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT04973605 2026-05-11

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Phase 2 Active not recruiting

Multiple Myeloma

NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT05688475 2026-05-11

A Rollover Study of CC-122

12 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06230224 2026-05-11

OLYMPIA-4

216 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04923893 2026-05-08

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05083169 2026-05-08

MajesTEC-3

587 enrolled 1 FDA

Multiple Myeloma

NCT05438043 2026-05-08

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT05552222 2026-05-08

MajesTEC-7

1,590 enrolled

Phase 2 Active not recruiting

Multiple Myeloma

NCT06577025 2026-05-08

aMMbition

43 enrolled

Multiple Myeloma

NCT06824467 2026-05-08

TroFuse-022

Phase 3 Not yet recruiting

770 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07569757 2026-05-08

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

260 enrolled

Multiple Myeloma

NCT06413498 2026-05-07

iMMagine-3

450 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04126200 2026-05-06

DREAMM 5

208 enrolled 5 charts

Phase 2/3 Active not recruiting

Multiple Myeloma

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06106945 2026-05-06

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

226 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04663347 2026-05-05

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05020236 2026-05-05

MAGNETISMM-5

944 enrolled

Multiple Myeloma

NCT06136624 2026-05-05

OMAHA-003

1,310 enrolled

Phase 1/2 Active not recruiting

Prostate Cancer Metastatic

NCT02343042 2026-05-04

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Phase 4 Terminated

141 enrolled

Multiple Myeloma

NCT03319667 2026-05-04

IMROZ

475 enrolled 1 FDA

Multiple Myeloma

NCT05583617 2026-05-04

PLYCOM

200 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07560449 2026-05-01

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

162 enrolled

Malignant Plasma Cell Neoplasms

NCT07391657 2026-04-30

DURGA-4

508 enrolled

Multiple Myeloma

NCT06104449 2026-04-27

MK-5684-005

Phase 1 Completed

7 enrolled

Prostatic Neoplasms

NCT05090566 2026-04-24

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Phase 2 Terminated

46 enrolled 15 charts

Multiple Myeloma

NCT04246047 2026-04-23

DREAMM 7

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT06868654 2026-04-23

DREAMM 7

72 enrolled 10 charts